Transcriptional repression of SIRT1 by protein inhibitor of activated STAT 4 (PIAS4) in hepatic stellate cells contributes to liver fibrosis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Sun, Lina ^a,b   Fan, Zhiwen ^a,c   Chen, Junliang ^a,d   Tian, Wenfang ^a   Li, Min ^a   Xu, Huihui ^a   Wu, Xiaoyan ^a   Shao, Jing ^e   Bian, Yaoyao ^e   Fang, Mingming ^a,f   Xu, Yong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^d JIANGNAN UNIVERSITY   (China)

^e NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^f Jiangsu Jiankang Vocational Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GLUCOSE; PROTEIN INHIBITOR OF ACTIVATED STAT; SIRTUIN 1; SMAD3 PROTEIN; SMALL INTERFERING RNA;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; COMPLICATION; CYTOLOGY; DISEASE MODEL; DOWN REGULATION; DRUG EFFECT; GENETICS; HEPATIC STELLATE CELL; LIVER; LIVER CIRRHOSIS; MALE; METABOLISM; MOUSE; MOUSE MUTANT; NONALCOHOLIC FATTY LIVER; PATHOLOGY; RAT; RNA INTERFERENCE; UPREGULATION;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ESTROGENS; GLUCOSE; HEPATIC STELLATE CELLS; LIVER; LIVER CIRRHOSIS; MALE; MICE; MICE, OBESE; NON-ALCOHOLIC FATTY LIVER DISEASE; PROTEIN INHIBITORS OF ACTIVATED STAT; RATS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIRTUIN 1; SMAD3 PROTEIN; UP-REGULATION;

EID: 84975505073     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28432     Document Type: Article

References (45)

1. Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836-1846, doi: 10.1002/hep.24001 (2010).
2. Argo, C. K., Northup, P. G., Al-Osaimi, A. M. & Caldwell, S. H. Systematic review of risk factors for fibrosis progression in nonalcoholic steatohepatitis. Journal of hepatology 51, 371-379, doi: 10.1016/j.jhep.2009.03.019 (2009).
3. Tsochatzis, E. A., Bosch, J. & Burroughs, A. K. New therapeutic paradigm for patients with cirrhosis. Hepatology 56, 1983-1992, doi: 10.1002/hep.25915 (2012).
4. Starley, B. Q., Calcagno, C. J. & Harrison, S. A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51, 1820-1832, doi: 10.1002/hep.23594 (2010).
5. Friedman, S. L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiological reviews 88, 125-172, doi: 10.1152/physrev.00013.2007 (2008).
6. Farrell, G. C. & Larter, C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99-S112, doi: 10.1002/hep.20973 (2006).
7. Kondou, H. et al. A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo. Journal of hepatology 39, 742-748 (2003).
8. Tian, W. et al. Myocardin-related transcription factor A (MRTF-A) plays an essential role in hepatic stellate cell activation by epigenetically modulating TGF-beta signaling. The international journal of biochemistry & cell biology 71, 35-43, doi: 10.1016/j. biocel.2015.12.005 (2016).
9. Fan, Z. et al. MKL1 is an epigenetic modulator of TGF-beta induced fibrogenesis. Biochimica et biophysica acta 1849, 1219-1228, doi: 10.1016/j.bbagrm.2015.07.013 (2015).
10. Moustakas, A., Souchelnytskyi, S. & Heldin, C. H. Smad regulation in TGF-beta signal transduction. Journal of cell science 114, 4359-4369 (2001).
11. Simonsson, M., Kanduri, M., Gronroos, E., Heldin, C. H. & Ericsson, J. The DNA binding activities of Smad2 and Smad3 are regulated by coactivator-mediated acetylation. The Journal of biological chemistry 281, 39870-39880, doi: 10.1074/jbc.M607868200 (2006).
12. Inoue, Y. et al. Smad3 is acetylated by p300/CBP to regulate its transactivation activity. Oncogene 26, 500-508, doi: 10.1038/sj.onc.1209826 (2007).
13. Li, J., Qu, X., Ricardo, S. D., Bertram, J. F. & Nikolic-Paterson, D. J. Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. The American journal of pathology 177, 1065-1071, doi: 10.2353/ajpath.2010.090923 (2010).
14. Sun, L. et al. A SUMOylation-dependent pathway regulates SIRT1 transcription and lung cancer metastasis. Journal of the National Cancer Institute 105, 887-898, doi: 10.1093/jnci/djt118 (2013).
15. Sun, L. et al. PIASy mediates hypoxia-induced SIRT1 transcriptional repression and epithelial-to-mesenchymal transition in ovarian cancer cells. Journal of cell science 126, 3939-3947, doi: 10.1242/jcs.127381 (2013).
16. Yamaguchi, K. et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45, 1366-1374, doi: 10.1002/hep.21655 (2007).
17. Paradis, V. et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 34, 738-744, doi: 10.1053/jhep.2001.28055 (2001).
18. Kamada, Y. et al. Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet. American journal of physiology. Gastrointestinal and liver physiology 301, G1031-1043, doi: 10.1152/ajpgi.00211.2011 (2011).
19. Schnabl, B. et al. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 34, 89-100, doi: 10.1053/jhep.2001.25349 (2001).
20. Feige, J. N. et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell metabolism 8, 347-358, doi: S1550-4131(08)00284-2 [pii] 10.1016/j.cmet.2008.08.017 (2008).
21. Anderson, N. & Borlak, J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacological reviews 60, 311-357, doi: 10.1124/pr.108.00001 (2008).
22. Brenner, C., Galluzzi, L., Kepp, O. & Kroemer, G. Decoding cell death signals in liver inflammation. Journal of hepatology 59, 583-594, doi: 10.1016/j.jhep.2013.03.033 (2013).
23. Clapper, J. R. et al. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. American journal of physiology. Gastrointestinal and liver physiology 305, G483-495, doi: 10.1152/ajpgi.00079.2013 (2013).
24. Smalling, R. L. et al. Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease. American journal of physiology. Gastrointestinal and liver physiology 305, G364-374, doi: 10.1152/ajpgi.00077.2013 (2013).
25. Murphy, S. K. et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology 145, 1076-1087, doi: 10.1053/j.gastro.2013.07.047 (2013).
26. Kohli, R. et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52, 934-944, doi: 10.1002/hep.23797 (2010).
27. Soufi, N. et al. Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice. The Journal of biological chemistry 289, 30177-30188, doi: 10.1074/jbc.M114.595850 (2014).
28. Sugimoto, R. et al. High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase. Liver international : official journal of the International Association for the Study of the Liver 25, 1018-1026, doi: 10.1111/j.1478-3231.2005.01130.x (2005).
29. Koo, J. H., Lee, H. J., Kim, W. & Kim, S. G. Endoplasmic Reticulum Stress in Hepatic Stellate Cells Promotes Liver Fibrosis via PERKMediated Degradation of HNRNPA1 and Up-regulation of SMAD2. Gastroenterology 150, 181-193, e188, doi: 10.1053/j. gastro.2015.09.039 (2016).
30. Simic, P. et al. SIRT1 Suppresses the Epithelial-to-Mesenchymal Transition in Cancer Metastasis and Organ Fibrosis. Cell reports 3, 1175-1186, doi: 10.1016/j.celrep.2013.03.019 (2013).
31. Kang, J. S., Saunier, E. F., Akhurst, R. J. & Derynck, R. The type I TGF-beta receptor is covalently modified and regulated by sumoylation. Nature cell biology 10, 654-664, doi: ncb1728 [pii] 10.1038/ncb1728 (2008).
32. Lee, P. S., Chang, C., Liu, D. & Derynck, R. Sumoylation of Smad4, the common Smad mediator of transforming growth factor-beta family signaling. The Journal of biological chemistry 278, 27853-27863, doi: 10.1074/jbc.M301755200 (2003).
33. Khodzhigorova, A. et al. Inhibition of sumoylation prevents experimental fibrosis. Annals of the rheumatic diseases 71, 1904-1908, doi: 10.1136/annrheumdis-2012-201746 (2012).
34. Stankovic-Valentin, N. et al. An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity. Molecular and cellular biology 27, 2661-2675, doi: MCB.01098-06 [pii] 10.1128/MCB, 01098-06 (2007).
35. Seki, E. & Schwabe, R. F. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology 61, 1066-1079, doi: 10.1002/hep.27332 (2015).
36. Barbero-Becerra, V. J. et al. The interplay between hepatic stellate cells and hepatocytes in an in vitro model of NASH. Toxicology in vitro: an international journal published in association with BIBRA 29, 1753-1758, doi: 10.1016/j.tiv.2015.07.010 (2015).
37. Pradere, J. P. et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology 58, 1461-1473, doi: 10.1002/hep.26429 (2013).
38. Schneiderhan, W. et al. Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. Hepatology 34, 729-737, doi: 10.1053/jhep.2001.27828 (2001).
39. Li, P. et al. Interferon gamma (IFN-gamma) disrupts energy expenditure and metabolic homeostasis by suppressing SIRT1 transcription. Nucleic acids research 40, 1609-1620, doi: gkr984 [pii]10.1093/nar/gkr984 (2012).
40. Weng, X. et al. Sin3B mediates collagen type I gene repression by interferon gamma in vascular smooth muscle cells. Biochemical and biophysical research communications 447, 263-270, doi: 10.1016/j.bbrc.2014.03.140 (2014).
41. Fang, F. et al. Myocardin-related transcription factor A mediates OxLDL-induced endothelial injury. Circulation research 108, 797-807, doi: CIRCRESAHA.111.240655 [pii]10.1161/CIRCRESAHA.111, 240655 (2011).
42. Fang, F. et al. Proinflammatory stimuli engage brahma related gene 1 and brahma in endothelial injury. Circulation research 113, 986-996, doi: 10.1161/CIRCRESAHA.113.301296 (2013).
43. Tian, W. et al. Myocardin related transcription factor A programs epigenetic activation of hepatic stellate cells. Journal of hepatology 62, 165-174, doi: 10.1016/j.jhep.2014.07.029 (2015).
44. Fang, M. et al. HDAC4 mediates IFN-gamma induced disruption of energy expenditure-related gene expression by repressing SIRT1 transcription in skeletal muscle cells. Biochimica et biophysica acta 1859, 294-305, doi: 10.1016/j.bbagrm.2015.11.010 (2015).
45. Tian, W. et al. Brahma-related gene 1 bridges epigenetic regulation of proinflammatory cytokine production to steatohepatitis in mice. Hepatology 58, 576-588, doi: 10.1002/hep.26207 (2013).